Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis

Hiroshi Nagaya, Daijo Inaguma, Akimitsu Kitagawa, Minako Murata, Yutaka Kamimura, Kyoko Hamaguchi, Miho Tatematsu, Sachiyo Suzuki, Kei Kurata, Yukio Yuzawa, Seiichi Matsuo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Darbepoetin alfa, which has a much longer half-life than recombinant human erythropoietin, is used to treat renal anemia. However, there are few reports investigating the efficacy of darbepoetin alfa administered every 2 weeks (Q2W). Methods: We performed the single-center, prospective, and randomized study in chronic hemodialysis patients. Clinically stable patients on hemodialysis were recruited, and darbepoetin alfa 15-40 μg/week was administered intravenously once a week (QW) to achieve a hemoglobin (Hb) level of 10.5-12.0 g/dl for 8 weeks prior to randomization. The patients were randomly assigned to 2 different dosing frequency groups: once a week (QW) or every 2 weeks (Q2W). We switched to a double dose in the Q2W group. We measured Hb level every 2 weeks and administered darbepoetin alfa to achieve an Hb level of 10.5-11.5 g/dl. The primary endpoints were the weekly dose of darbepoetin alfa administered at week 24. Results: We assigned 19 and 20 patients into QW and Q2W, respectively. There were no significant differences between the groups in Hb, transferrin saturation, ferritin, and weekly dose of darbepoetin alfa at end of the baseline period. There was no significant difference in Hb level at week 24, at which time the weekly dose requirement and dose per dry body weight were much higher in the Q2W than in the QW group. Conclusion: Administration of darbepoetin alfa Q2W could maintain Hb level similarly to to that obtained QW, but we did not confirm efficiency at a higher dose requirement or blood pressure elevation.

Original languageEnglish
Pages (from-to)158-163
Number of pages6
JournalClinical and Experimental Nephrology
Volume14
Issue number2
DOIs
Publication statusPublished - 01-04-2010

Fingerprint

Renal Dialysis
Hemoglobins
Transferrin
Ferritins
Random Allocation
Erythropoietin
Darbepoetin alfa
Half-Life
Anemia
Body Weight
Prospective Studies
Blood Pressure
Kidney

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Nagaya, Hiroshi ; Inaguma, Daijo ; Kitagawa, Akimitsu ; Murata, Minako ; Kamimura, Yutaka ; Hamaguchi, Kyoko ; Tatematsu, Miho ; Suzuki, Sachiyo ; Kurata, Kei ; Yuzawa, Yukio ; Matsuo, Seiichi. / Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. In: Clinical and Experimental Nephrology. 2010 ; Vol. 14, No. 2. pp. 158-163.
@article{ad3b5c4a3a1546a0a6551ba4964ce1fe,
title = "Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis",
abstract = "Background: Darbepoetin alfa, which has a much longer half-life than recombinant human erythropoietin, is used to treat renal anemia. However, there are few reports investigating the efficacy of darbepoetin alfa administered every 2 weeks (Q2W). Methods: We performed the single-center, prospective, and randomized study in chronic hemodialysis patients. Clinically stable patients on hemodialysis were recruited, and darbepoetin alfa 15-40 μg/week was administered intravenously once a week (QW) to achieve a hemoglobin (Hb) level of 10.5-12.0 g/dl for 8 weeks prior to randomization. The patients were randomly assigned to 2 different dosing frequency groups: once a week (QW) or every 2 weeks (Q2W). We switched to a double dose in the Q2W group. We measured Hb level every 2 weeks and administered darbepoetin alfa to achieve an Hb level of 10.5-11.5 g/dl. The primary endpoints were the weekly dose of darbepoetin alfa administered at week 24. Results: We assigned 19 and 20 patients into QW and Q2W, respectively. There were no significant differences between the groups in Hb, transferrin saturation, ferritin, and weekly dose of darbepoetin alfa at end of the baseline period. There was no significant difference in Hb level at week 24, at which time the weekly dose requirement and dose per dry body weight were much higher in the Q2W than in the QW group. Conclusion: Administration of darbepoetin alfa Q2W could maintain Hb level similarly to to that obtained QW, but we did not confirm efficiency at a higher dose requirement or blood pressure elevation.",
author = "Hiroshi Nagaya and Daijo Inaguma and Akimitsu Kitagawa and Minako Murata and Yutaka Kamimura and Kyoko Hamaguchi and Miho Tatematsu and Sachiyo Suzuki and Kei Kurata and Yukio Yuzawa and Seiichi Matsuo",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s10157-009-0251-x",
language = "English",
volume = "14",
pages = "158--163",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "2",

}

Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. / Nagaya, Hiroshi; Inaguma, Daijo; Kitagawa, Akimitsu; Murata, Minako; Kamimura, Yutaka; Hamaguchi, Kyoko; Tatematsu, Miho; Suzuki, Sachiyo; Kurata, Kei; Yuzawa, Yukio; Matsuo, Seiichi.

In: Clinical and Experimental Nephrology, Vol. 14, No. 2, 01.04.2010, p. 158-163.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis

AU - Nagaya, Hiroshi

AU - Inaguma, Daijo

AU - Kitagawa, Akimitsu

AU - Murata, Minako

AU - Kamimura, Yutaka

AU - Hamaguchi, Kyoko

AU - Tatematsu, Miho

AU - Suzuki, Sachiyo

AU - Kurata, Kei

AU - Yuzawa, Yukio

AU - Matsuo, Seiichi

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: Darbepoetin alfa, which has a much longer half-life than recombinant human erythropoietin, is used to treat renal anemia. However, there are few reports investigating the efficacy of darbepoetin alfa administered every 2 weeks (Q2W). Methods: We performed the single-center, prospective, and randomized study in chronic hemodialysis patients. Clinically stable patients on hemodialysis were recruited, and darbepoetin alfa 15-40 μg/week was administered intravenously once a week (QW) to achieve a hemoglobin (Hb) level of 10.5-12.0 g/dl for 8 weeks prior to randomization. The patients were randomly assigned to 2 different dosing frequency groups: once a week (QW) or every 2 weeks (Q2W). We switched to a double dose in the Q2W group. We measured Hb level every 2 weeks and administered darbepoetin alfa to achieve an Hb level of 10.5-11.5 g/dl. The primary endpoints were the weekly dose of darbepoetin alfa administered at week 24. Results: We assigned 19 and 20 patients into QW and Q2W, respectively. There were no significant differences between the groups in Hb, transferrin saturation, ferritin, and weekly dose of darbepoetin alfa at end of the baseline period. There was no significant difference in Hb level at week 24, at which time the weekly dose requirement and dose per dry body weight were much higher in the Q2W than in the QW group. Conclusion: Administration of darbepoetin alfa Q2W could maintain Hb level similarly to to that obtained QW, but we did not confirm efficiency at a higher dose requirement or blood pressure elevation.

AB - Background: Darbepoetin alfa, which has a much longer half-life than recombinant human erythropoietin, is used to treat renal anemia. However, there are few reports investigating the efficacy of darbepoetin alfa administered every 2 weeks (Q2W). Methods: We performed the single-center, prospective, and randomized study in chronic hemodialysis patients. Clinically stable patients on hemodialysis were recruited, and darbepoetin alfa 15-40 μg/week was administered intravenously once a week (QW) to achieve a hemoglobin (Hb) level of 10.5-12.0 g/dl for 8 weeks prior to randomization. The patients were randomly assigned to 2 different dosing frequency groups: once a week (QW) or every 2 weeks (Q2W). We switched to a double dose in the Q2W group. We measured Hb level every 2 weeks and administered darbepoetin alfa to achieve an Hb level of 10.5-11.5 g/dl. The primary endpoints were the weekly dose of darbepoetin alfa administered at week 24. Results: We assigned 19 and 20 patients into QW and Q2W, respectively. There were no significant differences between the groups in Hb, transferrin saturation, ferritin, and weekly dose of darbepoetin alfa at end of the baseline period. There was no significant difference in Hb level at week 24, at which time the weekly dose requirement and dose per dry body weight were much higher in the Q2W than in the QW group. Conclusion: Administration of darbepoetin alfa Q2W could maintain Hb level similarly to to that obtained QW, but we did not confirm efficiency at a higher dose requirement or blood pressure elevation.

UR - http://www.scopus.com/inward/record.url?scp=77952876072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952876072&partnerID=8YFLogxK

U2 - 10.1007/s10157-009-0251-x

DO - 10.1007/s10157-009-0251-x

M3 - Article

C2 - 19967423

AN - SCOPUS:77952876072

VL - 14

SP - 158

EP - 163

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 2

ER -